Antibacterial Prophylaxis in Patients with Cancer and Neutropenia

Authors:

Abstract
The recent studies by Bucaneve et al.1 and Cullen et al.2 (Sept. 8 issue) suggest that many patients with cancer and neutropenia may benefit from levofloxacin prophylaxis. Although the reports were published in tandem, their clinical implications differ fundamentally. Bucaneve et al. targeted “high-risk” patients (stem-cell transplant recipients or patients with leukemia) with anticipated neutropenia lasting more than seven days, a previously accepted approach.3

This publication has 13 references indexed in Scilit: